Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
      Description

      This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

      Conditions
      Advanced Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Mycosis FungoidesRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeRefractory Grade 1 Follicular LymphomaRefractory Grade 2 Follicular LymphomaRefractory Grade 3a Follicular LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaStage IB Mycosis Fungoides AJCC v7Stage II Mycosis Fungoides AJCC v7Stage III Cutaneous T-Cell Non-Hodgkin LymphomaStage III Mycosis Fungoides AJCC v7Stage IV Cutaneous T-Cell Non-Hodgkin LymphomaStage IV Mycosis Fungoides AJCC v7
      Talk to us